Large and Diverse Pipeline: Liver Cancer Market – Identifying and Commercializing First-in-Class Innovation
The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market.
View full press release